CellVoyant
We see the future in cells
We see the future in cells
CellVoyant
is an AI-first biotechnology company focused on revolutionizing stem cell-based therapies for chronic diseases. Using AI-first live cell imaging, the company aims to predict and optimize stem cell differentiation, enabling scalable manufacturing of various cells and tissues within the body. Founded in 2021 and headquartered in the United Kingdom, CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol, positioning itself at the intersection of cell biology, computer vision, engineering, and machine learning. The company's groundbreaking efforts are supported by a £7.60M Seed Round investment led by notable venture capital firms including Air Street Capital, Octopus Ventures, Horizons Ventures, and Verve Ventures, who have an impressive track record of early investments in industry pioneers such as DeepMind, Exscientia, Recursion, and Wayve. Additionally, CellVoyant benefits from the support of the founder/CEO of Abcam, a trailblazer in the antibody business. With a vision to industrialize next-generation scientific advancements, CellVoyant's bold and ambitious mission is underpinned by the support of leading investors and a multidisciplinary approach, positioning the company at the forefront of innovation in biotechnology and AI-driven healthcare solutions.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | £7.60M | 4 |
|
17 Jan 2024 |
No recent news or press coverage available for CellVoyant.
We care about your data, and we'd love to use cookies make your experience better.
